Integration of Different “-omics” Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells

Hematological malignancies frequently have a poor prognosis and often remain incurable. Drug resistance, severe side effects, and relapse are major problems of currently used drugs, and new candidate compounds are required for improvement of therapy success. The naphthoquinone shikonin derived from the Chinese medicinal herb, Lithospermum erythrorhizon, is a promising candidate for the next generation of chemotherapy. The basal cellular mechanism of shikonin is the direct targeting of mitochondria. Cytotoxicity screenings showed that the compound is particularly effective against leukemia cells suggesting an additional cellular mechanism. mRNA and miRNA microarrays were used to analyze changes in gene expression in leukemia cells after shikonin treatment and combined with stable-isotope dimethyl labeling for quantitative proteomics. The integration of bioinformatics and the three “-omics” assays showed that the PI3K-Akt-mTOR pathway was affected by shikonin. Deregulations of this pathway are frequently associated with cancerogenesis, especially in a wide range of hematological malignancies. The effect on the PI3K-Akt-mTOR axis was validated by demonstrating a decreased phosphorylation of Akt and a direct inhibition of the IGF1R kinase activity after shikonin treatment. Our results indicate that inhibiting the IGF1R-Akt-mTOR signaling cascade is a new cellular mechanism of shikonin strengthening its potential for the treatment of hematological malignancies.

• Publication year

  2013

• Venue

  Evidence-Based Complementary and Alternative Medicine

• Publication date

  2013-06-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1155/2013/818709PMID 23861714PMCID 3703888
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UniQua: a universal signal processor for MS-based qualitative and quantitative proteomics applications.

  2013cited by this paper
• A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

  2013cited by this paper
• mTOR signaling in growth control and disease.

  2012influential reference
• Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.

  2012cited by this paper
• Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML‐1107)

  2012cited by this paper
• The translational landscape of mTOR signalling steers cancer initiation and metastasis

  2012cited by this paper
• Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

  2012cited by this paper
• Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies

  2012cited by this paper
• Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention.

  2012cited by this paper
• Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells

  2012influential reference
• Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

  2012cited by this paper
• Lenalidomide for multiple myeloma.

  2012cited by this paper
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cited by this paper
• Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

  2010influential reference
• Lenalidomide for multiple myeloma

  2010cited by this paper
• Visual indicator for surfactant abundance in MS-based membrane and general proteomics applications.

  2010cited by this paper
• Curcumin Stimulates Reactive Oxygen Species Production and Potentiates Apoptosis Induction by the Antitumor Drugs Arsenic Trioxide and Lonidamine in Human Myeloid Leukemia Cell Lines

  2010cited by this paper
• Target profiling of small molecules by chemical proteomics.

  2009cited by this paper
• mTORC1 signalling and mRNA translation.

  2009cited by this paper
• AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

  2009cited by this paper
• Targeting the mTOR signaling network for cancer therapy.

  2009cited by this paper
• Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

  2008cited by this paper
• Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.

  2008cited by this paper
• Targeting the mTOR signaling network in cancer.

  2007cited by this paper
• Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

  2007cited by this paper
• Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

  2007cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• mTOR-targeted therapy of cancer with rapamycin derivatives.

  2005cited by this paper
• Combination of ‘omics’ data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in Rats and to identify potential biomarkers

  2004cited by this paper
• Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells.

  2003cited by this paper
• Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.

  2003cited by this paper
• Cellular pharmacology studies of shikonin derivatives

  2002cited by this paper
• Cancer Chemotherapy and Biotherapy: Principles and Practice

  2001cited by this paper
• Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.

  2000cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• A mammalian protein targeted by G1-arresting rapamycin–receptor complex

  1994cited by this paper
• Analysis of gene expression in single live neurons.

  1992cited by this paper

• Lipidomics: An emerging tool in aquatic toxicology research.

  2025cites this paper
• Network pharmacology to elucidate the role of phytotherapy in neurocognitive disorders.

  2025cites this paper
• Application of omics technologies in studies on antitumor effects of Traditional Chinese Medicine

  2024cites this paper
• The anti-leukemia activity and mechanisms of shikonin: a mini review

  2023cites this paper
• Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from Cajanus cajan (L.) Millsp.

  2022cites this paper
• Network Pharmacology of Adaptogens in the Assessment of Their Pleiotropic Therapeutic Activity

  2022cites this paper
• Application of radiation omics in the development of adverse outcome pathway networks: an example of radiation-induced cardiovascular disease

  2022cites this paper
• Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.

  2021cites this paper
• MicroRNA Interactome Multiomics Characterization for Cancer Research and Personalized Medicine: An Expert Review

  2021cites this paper
• (3,3’-Methylene)bis-2-hydroxy-1,4-naphthoquinones induce cytotoxicity against DU145 and PC3 cancer cells by inhibiting cell viability and promoting cell cycle arrest

  2021cites this paper
• Shikonin Derivatives from Onsoma visianii Decrease Expression of Phosphorylated STAT3 in Leukemia Cells and Exert Antitumor Activity

  2021cites this paper
• Activation of CaMKKβ-AMPK-mTOR pathway is required for autophagy induction by β,β-dimethylacrylshikonin against lung adenocarcinoma cells.

  2019cites this paper
• Pharmacological Properties and Derivatives of Shikonin-A Review in Recent Years.

  2019cites this paper
• Chinese Herbal Medicine-Based Cancer Therapy: Novel Anticancer Agents Targeting MicroRNAs to Regulate Tumor Growth and Metastasis.

  2019cites this paper
• Shikonin changes the lipopolysaccharide-induced expression of inflammation-related genes in macrophages

  2017cites this paper
• Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells.

  2017cites this paper
• Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.

  2017cites this paper
• Proteomics landscape of radiation-induced cardiovascular disease: somewhere over the paradigm

  2017cites this paper
• Quambalarine B, a Secondary Metabolite from Quambalaria cyanescens with Potential Anticancer Properties.

  2016cites this paper
• Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature.

  2016cites this paper
• Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells

  2016cites this paper
• A Systems Biology View on Bacterial Response to Temperature Shift

  2016cites this paper
• Biosynthesis of Natural Products and Synthetic Biology of Antitumor Drugs

  2015cites this paper
• Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

  2015cites this paper
• Integrative proteomics and targeted transcriptomics analyses in cardiac endothelial cells unravel mechanisms of long-term radiation-induced vascular dysfunction.

  2015cites this paper
• Multi –omics and metabolic modelling pipelines: challenges and tools for systems microbiology

  2015cites this paper
• Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids

  2015cites this paper
• Medicinal Plants and DNA Methylation of Cancer

  2015cites this paper
• Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells.

  2014cites this paper
• Sho-saiko-to, a traditional herbal medicine, regulates gene expression and biological function by way of microRNAs in primary mouse hepatocytes

  2014cites this paper